Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is set to capitalize on the growing market opportunity for early detection of esophageal cancer with their highly accurate molecular tests, EsoGuard and EsoCheck. Their progress with Medicare and potential positive coverage, as well as partnerships and strategic initiatives, position the company for growth and success. While recent financial results may have been lower than expected, Lucid plans to continue expanding their sales force and increasing awareness of their products, with support from a Buy rating and price target from Abbott Laboratories.

Bears say

Lucid Diagnostics is a commercial-stage medical diagnostics technology company that has recently seen growth momentum in commercial health plans and has successfully achieved reimbursement for its EsoGuard test. Despite a large market opportunity of approximately $2 billion, risks to achieving profitability include balance sheet/liquidity risks, delays in gaining regulatory approvals and reimbursements, and competition within the biotech/medtech industry.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.